About: Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2000 (uk) im Juni 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 2000 (ast) scientific article published on 01 June 2000 (en)
publication date	wds:Q73850903-9157FA17-0CC0-4833-A9B0-9436F61CBD4B
publication date	2000-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73850903-14240A6D-C566-4EAD-B58E-F5638E5308C4
language of work or name	English
cites work	wds:Q73850903-059986C6-59D0-44FF-96D8-1F846A8EE8FC wds:Q73850903-079D59BD-30F4-42CB-81A1-34F6A1A18216 wds:Q73850903-140FF7F2-1F08-4787-AB16-E6A72066384D wds:Q73850903-260297A9-EB7D-4AAB-B5E4-7FEB03DEDFBD wds:Q73850903-2EB54188-67FC-44B8-9D09-74A158CC0400 wds:Q73850903-2F5E45BE-04EF-4902-8389-18943A86BA1B wds:Q73850903-33084F72-C3A1-4F10-B3EC-40E8AB0A64DE wds:Q73850903-5A9E6D13-C545-42E4-8F9C-7C03BC43714C wds:Q73850903-62AAFAAE-E38C-4F70-9533-06417DCDC00E wds:Q73850903-787404F0-040C-4AFF-95F3-0CE7FBF2E382 wds:Q73850903-AE52EE7D-5FC3-47B8-B650-430D17B3EFE0 wds:Q73850903-B6BE0734-A9D6-401C-AF3C-7AA0229DC613 wds:Q73850903-BC2C083C-D255-4E7E-899B-1DA83A5C19D3 wds:Q73850903-C2C5E936-5F2E-4C62-8B34-987FCE53A348 wds:Q73850903-C2EFD76F-D630-4EBB-AFAA-2DA9CD9BAC27 wds:Q73850903-FA5167B4-A0BC-48D1-B5E1-09ADAC48B352
cites work	Radiosensitizing nucleosides Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck An in vivo model for squamous cell carcinoma of the head and neck. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrop 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase Acute reactions of the lip mucosa of mice to fractionated irradiations
author name string	wds:Q73850903-10CBB8C6-10B6-43EF-9BDE-094B3154CE0D wds:Q73850903-113E3244-4554-4C10-AFE3-A780FBE7A730 wds:Q73850903-25C4D647-13A9-43E2-AA82-CE7816BBF01D wds:Q73850903-31384F09-F397-45A1-9FD8-E8D71FBC543A wds:Q73850903-97230651-5B69-4900-A04F-862D3CD473FA wds:Q73850903-C811ADEE-5AA6-47E6-A481-5B16FC1023E8
author name string	M A Davis T S Lawrence A Eisbruch A T Pu A Orfali M T Fields
rdfs:label	Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) (en) Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (nl)
skos:prefLabel	Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) (en) Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (nl)
name	Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) (en) Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (nl)
author	wds:Q73850903-50514538-966D-4E50-9DCA-41B33D430B2A
author	Daniel P. Normolle
title	wds:Q73850903-44E7D276-53BB-4D5E-B14A-91FC55B4C97D
title	Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) (en)
page(s)	wds:Q73850903-8F4B4CE6-26B7-439C-AC2D-9F4754DAA17F
page(s)	785-791
instance of	wds:Q73850903-3E647CB0-5E40-49EC-B111-F3DDF3191195
instance of	scholarly article
PubMed ID	wds:Q73850903-F3776072-7EDC-4E6F-B8B8-F000F6F15FCD
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10837965
PubMed ID	10837965
published in	wds:Q73850903-3D1AA3BF-C767-45E2-A71C-29CB85F8F039
published in	International Journal of Radiation Oncology Biology Physics
issue	wds:Q73850903-436B0FE3-5AEA-4035-8656-D167449E28B2
volume	wds:Q73850903-E0F7B758-F919-4786-9AB6-0E0329A6C115
issue	3
volume	47
DOI	wds:Q73850903-6A6DF969-3E82-426B-81C2-8FB353A16530
DOI	http://dx.doi.org/10.1016/S0360-3016(00)00447-8
DOI	10.1016/S0360-3016(00)00447-8
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73850903
is cites work of	Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio Bone regeneration in defects compromised by radiotherapy Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer Effect of gemcitabine on acute and late radiation toxicity of skin and underlying soft tissues to single-dose irradiation in a nude mice model

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software